Navigation Links
University of Granada researchers identify changes in tumor cells that lead to metastasis
Date:1/17/2012

Researchers at the Centro de Genmica e Investigacin Oncolgica (GENYO) of which the University of Granada, Pfizer and the Andalusian Regional Government are members have identified the genetic and phenotypic changes that cause tumor progression and metastasis. The process of metastasis -which is the main cause of cancer death- is caused by tumor cells invading distant organs with no direct anatomical relationship with the organ originally affected. For this to happen, it is necessary that these cells which researchers call "circulating tumor cells" (CTCs) , travel to these organs through blood.

The researchers detected CTCs undergoing cell division in a breast cancer patient on systemic treatment. Thus, CTCs have been demonstrated both to be able to adapt to hostile microenvironments as blood, and to resist treatment and divide and proliferate in other organs and tissues, causing metastasis. So far, this behavior had not been observed in this type of microenvironments.

The results of this study were described in the article "Biodynamics of Circulating Tumor Cell, Tumor Microenvironment and Metastasis", published in the journals Cancer Biology & Therapy, Clinical Translational Oncoly y Annals of Oncology. The researchers found that breast cancer patients with circulating tumor cells (CTCs) at baseline tend to develop metastasis and have shorter disease-free survival after treatment. Thus, detecting CTCs during and after treatment allows physicians to identify which patients are responding favorably to chemotherapy. Consequently, patients with CTCs while receiving chemotherapy have shorter disease-free survival and lower overall survival rates. This is due to the fact that these cells are resistant to conventional treatments performed according to the genetic characteristics of the tumor. Therefore, CTCs can survive chemotherapy and produce metastasis to other organs.

More Efficient Individualized Treatments

University of Granada professor Jos Antonio Lorente -GENYO manager director and coordinator of the research group- affirms that the study of Circulating Tumor Cells (CTCs) is crucial "not only because they may be responsible for the development of metastasis, but also because they have genetic characteristics different to those found in the primary tumor and in metastatic cells. Such characteristics make these very aggressive cells resistant to the immunologic system and to the therapeutic agents generally used in cancer patients". Most of these treatments are targeted against proliferating tumor cells. Conversely, CTCs are found in a "dormant" phase, i.e. in a "non-proliferation" phase.

As these cells may indicate negative response to treatment, if they were isolated and genetically characterized, patients could be classified according to their chances of relapse, which would allow individualized follow-up.


'/>"/>
Contact: Dr. Jos Antonio Lorente Acosta. GENYO manager director
jlorente@ugr.es
34-958-637-079
University of Granada
Source:Eurekalert

Related medicine news :

1. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
2. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
3. Most pandemic plans in Ontario hospitals have not been tested: Queens University study
4. San Diego State University and BIOCOM Institute Receive $4.95 Million Grant: The BRIDGE Project, Linking Education to Employment in San Diegos Life Sciences Industry
5. Smithsonian Institution, Arizona State University announce education and research partnership
6. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
7. Giarmarco, Mullins & Horton, P.C. President Joseph F. Page to Speak at University of Michigan
8. Arizona State Universitys Decision Theater offers balance to an off-kilter world
9. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
10. Herzing University Online Launches Master and Bachelor of Science Degrees in Nursing
11. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 2017 , ... Miro is the ultimate smart media center that offers a ... TV shows and much more apps for user exploration. Its innovative acoustic design with ... 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi connection ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... 2017 , ... IndustryArchive.Org . is announcing a new way for B2B ... now only pay for B.A.N.T. quality sales leads based on the Sellers decision to ... new reality that B2B buyers are controlling the sales process via the Internet and ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... RGN-137, GtreeBNT Co., Ltd., received a positive response ... clinical trial design for RGN-137 to treat epidermolysis ... gel that incorporates Thymosin beta 4 ("Tß4") as ...
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
Breaking Medicine Technology: